GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncternal Therapeutics Inc (FRA:GTU) » Definitions » Net Margin %

Oncternal Therapeutics (FRA:GTU) Net Margin % : 0.00% (As of Mar. 2024)


View and export this data going back to . Start your Free Trial

What is Oncternal Therapeutics Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. Oncternal Therapeutics's Net Income for the three months ended in Mar. 2024 was €-7.72 Mil. Oncternal Therapeutics's Revenue for the three months ended in Mar. 2024 was €0.00 Mil. Therefore, Oncternal Therapeutics's net margin for the quarter that ended in Mar. 2024 was 0.00%.

The historical rank and industry rank for Oncternal Therapeutics's Net Margin % or its related term are showing as below:


FRA:GTU's Net Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -154.37
* Ranked among companies with meaningful Net Margin % only.

Oncternal Therapeutics Net Margin % Historical Data

The historical data trend for Oncternal Therapeutics's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oncternal Therapeutics Net Margin % Chart

Oncternal Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Oncternal Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Oncternal Therapeutics's Net Margin %

For the Biotechnology subindustry, Oncternal Therapeutics's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oncternal Therapeutics's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oncternal Therapeutics's Net Margin % distribution charts can be found below:

* The bar in red indicates where Oncternal Therapeutics's Net Margin % falls into.



Oncternal Therapeutics Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Oncternal Therapeutics's Net Margin for the fiscal year that ended in Dec. 2023 is calculated as

Net Margin=Net Income (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-36.202/0
= %

Oncternal Therapeutics's Net Margin for the quarter that ended in Mar. 2024 is calculated as

Net Margin=Net Income (Q: Mar. 2024 )/Revenue (Q: Mar. 2024 )
=-7.717/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Oncternal Therapeutics  (FRA:GTU) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.


Oncternal Therapeutics Net Margin % Related Terms

Thank you for viewing the detailed overview of Oncternal Therapeutics's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Oncternal Therapeutics (FRA:GTU) Business Description

Traded in Other Exchanges
Address
12230 El Camino Real, Suite 230, San Diego, CA, USA, 92130
Oncternal Therapeutics Inc is a clinical-stage oncology company developing first-in-class, novel therapies that target a broad spectrum of cancers with a large unmet medical need. The Company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to ROR1 (Receptor-tyrosine kinase-like Orphan Receptor 1), and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins. The Company is also developing ONCT-808, a CAR-T (chimeric antigen receptor T-cells) product candidate that targets ROR1 and ONCT-534, a dual-action androgen receptor inhibitor product candidate for the treatment of castration-resistant prostate and other androgen receptor-driven cancers.

Oncternal Therapeutics (FRA:GTU) Headlines

No Headlines